Etherington Robert Dee Buys 65,000 Shares of CLNN

CLNN's CEO made a notable insider purchase, acquiring 65,000 shares.

Written by EarningsIQ · Published Jun 15, 2026, 3:01 PM EDT · Updated Jun 15, 2026, 4:01 PM EDT

Key Points

On June 11, 2026, Etherington Robert Dee, President & CEO of CLNN, bought 65,000 shares at no cost.
CLNN shares traded at around $5.78, with several institutional investors adjusting their positions.
Analysts from HC Wainwright & Co. and D. Boral Capital maintain a 'buy' rating with high price targets.

On June 11, 2026, Etherington Robert Dee, the President and CEO of CLNN, made a significant insider purchase by acquiring 65,000 shares of the company. This transaction was recorded at no purchase price.

Other Institutional Activity in CLNN

Several institutional investors have also been active with CLNN shares. Boxer Capital Management, LLC increased its holdings by 277,778 shares, bringing its total to 477,515 shares valued at approximately $2.35 million. Meanwhile, Symbiosis Capital Partners, LLC reduced its position by 339,401 shares, now holding 431,094 shares worth about $2.12 million. Vanguard Capital Management LLC added 308,230 shares, ending with the same number of shares valued at $1.52 million. Scoggin Management LP and Ensign Peak Advisors, Inc also increased their stakes, with changes of 25,000 and 143,511 shares respectively.

CLNN Stock Snapshot

Shares of CLNN are trading around $5.78. The stock has seen various institutional movements, reflecting its dynamic market presence. Despite the lack of detailed financial metrics, the recent insider activity suggests ongoing interest and confidence in the company's potential.

Insider Buying and Selling at Clene Inc.

Alongside Etherington's purchase, other executives have also been acquiring shares. On June 11, 2026, Morgan Brown, the Chief Financial Officer, bought 15,000 shares, while Mark Mortenson, the Chief Science Officer, purchased 45,000 shares. These transactions were also recorded at no purchase price, indicating a coordinated acquisition effort by the company's leadership.

Analysts Set New Price Targets

Analysts remain optimistic about CLNN's prospects. On May 4, 2026, HC Wainwright & Co. reiterated a 'buy' rating with a price target of $31. D. Boral Capital also maintained a 'buy' rating with a $23 price target on the same day. Canaccord Genuity had previously set a target of $48, reinforcing the positive sentiment among analysts.

About CLNN

CLNN is a company operating in the healthcare sector, focusing on innovative treatments and therapies. The company is led by CEO Etherington Robert Dee and is committed to advancing its research and development efforts.

Bottom Line

The insider purchases by CLNN's top executives, including CEO Etherington Robert Dee, highlight their confidence in the company's future. While 13F filings provide a historical snapshot and don't necessarily reflect current positions, the recent insider activity and analyst ratings suggest a positive outlook. Investors often track such moves for insights into the company's potential trajectory.